This scientific statement presents considerations for clinical management regarding the
assessment and risk reduction of select pediatric populations at high risk for premature …

Pediatric heart transplantation is standard of care for children with end-stage heart failure.
The diverse age range, diagnoses, and practice variations continue to challenge the …

Cardiac allograft vasculopathy (CAV) is a challenging complication of heart transplantation.
CAV pathophysiology is incompletely understood, standard screening modalities such as …

Background Heart transplantation has become the standard of care for pediatric patients
with end‐stage heart disease, and outcomes have consistently improved over the last few …

Common indications for PHTx include end-stage congenital heart disease and
cardiomyopathy. Current median graft survival among PHTx recipients ranges from 13 to 22 …

Background Cardiac allograft vasculopathy (CAV) is a leading cause of graft failure in
pediatric heart transplant recipients (HTRs). Early statin use has been shown to reduce CAV …

Cardiac allograft vasculopathy (CAV)—mediated by a heterogeneous myriad of immune and
non-immune factors, which contribute to the progressive and diffuse thickening of the arterial …

Cardiac allograft vasculopathy (CAV) remains one of the main long‐term complications after
heart transplantation. We performed a systematic review focused on articles published in the …

Together with heart-healthy lifestyle habits, statins serve as the cornerstone of primary and
secondary prevention of atherosclerotic cardiovascular disease in adults. Several …

Pediatric heart transplant has become the standard of care for end-stage heart disease in
children throughout the world. The number of transplants has grown dramatically since the …